Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, ...
Annexon Narrows Loss in Fiscal Q2
Annexon ( NASDAQ:ANNX ) , a clinical-stage biopharmaceutical company developing therapies for serious autoimmune and neurodegenerative diseases, released its second quarter 2025 financial results on August 14, 2025. The company's net loss per share ( GAAP ) was $0.34, beating analyst expectations ...
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument ( formerly ANX007 ) for Dry Age-Related Macular Degeneration ( AMD ) with Geographic Atrophy
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation ...
New Strong Sell Stocks for July 22nd
BLTE, DDD and ANNX have been added to the Zacks Rank #5 (Strong Sell) List on July 22, 2025.
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration ( AMD ) with Geographic Atrophy ( GA )
Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ...
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 ( GLOBE NEWSWIRE ) -- Nkarta, Inc. ( Nasdaq: NKTX ) , a clinical-stage biopharmaceutical company developing engineered natural killer ( NK ) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., May 16, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, ...
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Annexon ( NASDAQ:ANNX ) , Camtek ( NASDAQ:CAMT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut Annexon, Inc. ANNX price target from $20 to $14.
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised ZoomInfo Technologies Inc. ZI price target from $9 to $11.
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome ( GBS ) at the 2025 PNS Meeting - Annexon ( NASDAQ:ANNX )
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study ( IGOS ) of the Real-World Evidence ( RWE ) Results Showing Improved Outcomes with Tanruprubart ( formerly ANX005 ) Compared to Current Standards of Care in Matched Patient Populations
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome ( GBS ) at the 2025 PNS Meeting
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study ( IGOS ) of the Real-World Evidence ( RWE ) Results Showing Improved Outcomes with Tanruprubart ( formerly ANX005 ) Compared to Current Standards of Care in Matched Patient Populations ...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Annexon ( NASDAQ:ANNX )
BRISBANE, Calif., April 16, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc.
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., April 16, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, ...
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder - Annexon ( NASDAQ:ANNX )
At Week 1, patients were 14x more likely to complete a mobility test and saw a 2+ point ONLS improvement with tanruprubart. At Week 26, twice as many patients on tanruprubart had no limitations on ONLS vs placebo; ICU stays were shorter by about a week. Feel unsure about the market's next move?
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome ( GBS ) at American Academy of Neurology ( AAN ) 2025 Annual Meeting - Annexon ( NASDAQ:ANNX )
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points Educational Symposium Focuses on Advancing GBS Care and Role of Classical Complement Pathway
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome ( GBS ) at American Academy of Neurology ( AAN ) 2025 Annual Meeting
Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points ...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., March 17, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, ...
Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, ...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, ...
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin ( IVIg ) or Plasma Exchange ( PE ) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome ( GBS )
Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of ...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Nov. 15, 2024 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, ...
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting - Annexon ( NASDAQ:ANNX )
Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data Expected Second Half 2026 BRISBANE, Calif., Oct. 21, 2024 ( GLOBE NEWSWIRE ) -- Annexon, Inc.
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Enhanced protection of vision with ANX007 treatment in healthier eyes ...
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress - Annexon ( NASDAQ:ANNX )
Only Program that has Demonstrated Significant Vision Protection in Standard and Low Light Conditions and Significant Preservation of Photoreceptors in the Fovea Region Critical for Visual Acuity ARCHER II Phase 3 Pivotal Program in GA Underway with Data Expected Second Half 2026
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., Aug. 16, 2024 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to two new non-executive employees ...
Is Arbutus Biopharma ( ABUS ) Outperforming Other Medical Stocks This Year?
Here is how Arbutus Biopharma (ABUS) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., July 16, 2024 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing novel therapies for neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms ...
Is CareCloud ( CCLD ) Outperforming Other Medical Stocks This Year?
Here is how CareCloud, Inc. (CCLD) and Annexon, Inc. (ANNX) have performed compared to their sector so far this year.
Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday - Bank of New York Mellon ( NYSE:BK )
U.S. stocks were higher, with the Nasdaq Composite index gaining around 100 points on Friday. Shares of The Bank of New York Mellon Corporation BK rose during Friday's session following better-than-expected quarterly financial results.
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting - Annexon ( NASDAQ:ANNX )
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 ( GLOBE NEWSWIRE ) -- ...
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation ...
Are Medical Stocks Lagging Annexon ( ANNX ) This Year?
Here is how Annexon, Inc. (ANNX) and CareCloud, Inc. (CCLD) have performed compared to their sector so far this year.
Here's Why Annexon ( ANNX ) Is a Great 'Buy the Bottom' Stock Now
After losing some value lately, a hammer chart pattern has been formed for Annexon (ANNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
Exton, Pennsylvania, June 27, 2024 ( GLOBE NEWSWIRE ) -- Prior to 2023, there was no treatment for GA, a progressive form of dry age-related macular degeneration that results in blindness. That changed in early 2023 when Apellis gained FDA approval for Syfovre, followed by Iveric Bio/Astellas' ...
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints ...
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting - Annexon ( NASDAQ:ANNX )
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS BRISBANE, Calif., June 18, 2024 ( GLOBE NEWSWIRE ) -- ...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., June 17, 2024 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement ...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Annexon ( NASDAQ:ANNX )
BRISBANE, Calif., June 17, 2024 ( GLOBE NEWSWIRE ) -- Annexon, Inc.
Is Annexon ( ANNX ) Stock Outpacing Its Medical Peers This Year?
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
Annexon Announces Pricing of $125 Million Underwritten Public Offering
Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the pricing of its previously ...
Annexon Announces Pricing of $125 Million Underwritten Public Offering
BRISBANE, Calif., June 05, 2024 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, ...
Annexon ( ANNX ) Up as Phase III Neuro Disorder Study Meets Goals
Annexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of its lead candidate, ANX005, in the phase III study for Guillain-Barre syndrome.
Wall Street Analysts Think Annexon ( ANNX ) Could Surge 133.72%: Read This Before Placing a Bet
The consensus price target hints at a 133.7% upside potential for Annexon (ANNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - DouYu Intl Hldgs ( NASDAQ:DOYU )
U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Wednesday. Shares of DouYu International Holdings Limited DOYU fell in today's pre-market trading following first-quarter results.
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Stitch Fix ( NASDAQ:SFIX )
Shares of Stitch Fix, Inc. SFIX rose sharply in today's pre-market trading following better-than-expected third-quarter financial results. Stitch Fix reported quarterly losses of 18 cents per share which beat the analyst consensus estimate of losses of 24 cents by 25%.
Annexon Announces Proposed Public Offering of Common Stock
BRISBANE, Calif., June 04, 2024 ( GLOBE NEWSWIRE ) -- Annexon, Inc. ( Nasdaq: ANNX ) , a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, ...
Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings - Designer Brands ( NYSE:DBI )
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 200 points on Tuesday. The Dow traded up 0.53% to 38,774.55 while the NASDAQ rose 0.29% to 16,877.87. The S&P 500 also rose, gaining, 0.25% to 5,296.54. Real estate shares rose by 1.3% on Tuesday.
Why is Annexon Stock Trading Higher On Tuesday? - Annexon ( NASDAQ:ANNX )
On Tuesday, Annexon Inc ANNX released topline results from its Phase 3 trial in patients with Guillain-Barré syndrome ( GBS ) , an autoimmune condition in which the immune system attacks the nerves. As Guillain-Barre syndrome progresses, muscle weakness can turn into paralysis.
Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday - Saia ( NASDAQ:SAIA )
U.S. stocks were mixed, with the Dow Jones index gaining around 20 points on Tuesday. Shares of Saia Inc SAIA rose sharply during today's pre-market trading session after the company reported an 18% increase in LTL shipments per workday in April. Saia shares jumped 12.3% to $452.00 on Tuesday.
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome - Annexon ( NASDAQ:ANNX )
Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle ...
